Q1 Earnings Forecast for Longeveron Issued By Zacks Research

Longeveron Inc. (NASDAQ:LGVN) – Investment analysts at Zacks Research issued their Q1 2026 EPS estimates for shares of Longeveron in a research note issued to investors on Tuesday, February 17th. Zacks Research analyst B. Sorensen expects that the company will earn ($1.84) per share for the quarter. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Zacks Research also issued estimates for Longeveron’s Q2 2026 earnings at ($2.02) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($4.68) EPS and FY2027 earnings at ($1.65) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Longeveron in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Longeveron presently has a consensus rating of “Hold” and a consensus price target of $6.50.

Longeveron Price Performance

Shares of NASDAQ LGVN opened at $0.56 on Friday. The firm has a fifty day moving average price of $0.56 and a 200-day moving average price of $0.71. The stock has a market cap of $11.94 million, a PE ratio of -0.53 and a beta of 0.21. Longeveron has a 1 year low of $0.49 and a 1 year high of $1.92.

Institutional Trading of Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron as of its most recent SEC filing. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.